Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Light-Activated Sperm Restore Fertility

By using pulses of light to control sperm function, scientists have not only induced vigorous beating in formerly listless flagella, they have also restored fertility to once sterile mice. The scientists achieved all this through an application of optogenetics

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

By using pulses of light to control sperm function, scientists have not only induced vigorous beating in formerly listless flagella, they have also restored fertility to once sterile mice. The scientists achieved all this through an application of optogenetics, which involves the insertion of genes that code for light-sensitive proteins.

To date, optogenetics has been most prominent in the neurosciences, where light-sensitive ion channels are used to control the electrical activity of nerve cells. But optogenetics is becoming more versatile. As the current study demonstrates, optogenetics can be used to switch messenger-mediated signaling pathways in cells on and off.

Scientists from the Center of Advanced European Studies and Research (caesar) inserted a gene expressing a photoactivated adenylyl cyclase into mice that lacked the endogenous enzyme. Sperm of these mice are usually non-motile, and the mice consequently infertile. After simulation of these sperm with blue light, they produce cyclic AMP (cAMP), start to swim again, and are even able to fertilize eggs.

These results were reported January 20 in the journal eLife, in an article entitled “Controlling fertilization and cAMP signaling in sperm by optogenetics.”

The light-activated adenylyl cyclase had been discovered earlier in soil bacteria—hence the enzyme’s acronym bPAC, for bacterial photoactivated adenylate cyclase. In transgenic sperm, bPAC mimics the action of the endogenous soluble adenylyl cyclase (SACY) that is required for motility and fertilization.

“Light-stimulation rapidly elevates cAMP, accelerates the flagellar beat, and thereby changes swimming behavior of sperm,” wrote the authors of the eLife article. “Furthermore, bPAC replaces endogenous adenylyl cyclase activity. In mutant sperm lacking the bicarbonate-stimulated SACY activity, bPAC restored motility after light-stimulation and, thereby, enabled sperm to fertilize oocytes in vitro.”

The enzymes known as adenylate cyclases synthesize cAMP, an important cellular messenger. cAMP controls a wide range of functions such as heart rate, the sense of smell, learning, memory formation, and the fertilization of eggs. By optogenetically influencing adenylate cyclase levels, and thereby cAMP levels, the caesar scientists have shown that it is possible to control the behaviors of single cells, and to restore a fundamental biological process such as fertilization.

Anticipating future work, the scientists noted that the optogenetic toolkit has been recently expanded by a light-activated phosphodiesterase (LAPD) that hydrolyses cyclic nucleotides upon stimulation by red light. “A combination of LAPD and bPAC with fluorescent cAMP biosensors holds great promise to map the dynamics of cAMP signaling in live cells in precise spatio-temporal and quantitative terms,” they explained. “These findings encourage future studies to explore the full potential of controlling cellular messengers by optogenetics.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →